Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant gemcitabine–cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial

Published:2024-09-10 Issue: Volume: Page:
ISSN:2662-1347
Container-title:Nature Cancer
language:en
Short-container-title:Nat Cancer

Author:

Li Kaiwen,Zhong Wenlong,Fan Jinhai,Wang Shaogang,Yu Dexin,Xu Tao,Lyu Jiaju,Wu Shaoxu,Qin Tao,Wu Zhuo,Xu Longhao,Wu Kaijie,Liu Zheng,Hu Zhiquan,Li Fan,Wang Jinyou,Wang Qi,Min Jie,Zhang Zhiqiang,Yu Luping,Ding Sentai,Huang Longfei,Zhao Tingting,Huang Jian^ORCID,Lin Tianxin^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s43018-024-00822-0.pdf

Reference62 articles.

1. Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796–2810 (2016).

2. Alfred Witjes, J. et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17–31 (2024).

3. Flaig, T. W. et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin. Cancer Res. 27, 2435–2441 (2021).

4. Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241–249 (2015).

5. Iyer, G. et al. Neoadjuvant gemcitabine–cisplatin plus radical cystectomy–pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience. Clin. Genitourin. Cancer 18, 387–394 (2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP